HSP105 Inhibition Counteracts Key Oncogenic Pathways and Hampers the Growth of Human Aggressive B-Cell Non-Hodgkin Lymphoma

癌症研究 生物 淋巴瘤 基因沉默 热休克蛋白 生发中心 B细胞 抗体 癌症 细胞生长 免疫学 分子生物学 基因 遗传学 生物化学
作者
Roberta Zappasodi,Alessandra Cavanè,Monica Tortoreto,Cristina Tringali,Giusi Ruggiero,Lorenzo Castagnoli,Bruno Venerando,Nadia Zaffaroni,Serenella M. Pupa,Alessandro M. Gianni,Massimo Di Nicola
出处
期刊:Blood [Elsevier BV]
卷期号:120 (21): 1562-1562
标识
DOI:10.1182/blood.v120.21.1562.1562
摘要

Abstract Abstract 1562 Our previous findings have made it clear that the significant clinical efficacy attained by dendritic cell-based vaccination in relapsed B-cell non-Hodgkin lymphoma (B-NHL) patients is firmly associated with multifaceted immunologic responses, including the development of anti-heat shock protein (HSP)105 humoral immunity (Di Nicola et al., Blood 2009 113:18–27; Zappasodi et al., Cancer Res. 2010 70:9062–9072; Zappasodi et al., Blood 2011 118:4421–4430). Human HSP105 is a high-molecular-weight chaperone constitutively expressed at low levels within the cytoplasm, and can also be induced in the nucleus by various forms of stress. It is overexpressed in several solid tumors, including melanoma, breast, thyroid and gastroenteric cancers. We have recently shown that this is also true for B-NHLs, in which HSP105 levels increase in function of their aggressiveness and proliferation index (Zappasodi et al., Blood 2011 118:4421–4430). Accordingly, in normal lymph nodes HSP105 expression is confined to the hyper-proliferating germinal center (GC) B cells, suggesting its involvement in the potentially oncogenic GC reactions. We have now set out to clarify the functional role of HSP105 in B-NHLs by stably silencing its expression in the Namalwa aggressive lymphoma cell line. Namalwa cells were infected by using a lentiviral vector carrying a HSP105-targeting pre-microRNA sequence and the Emerald Green Fluorescent Protein (EmGFP) gene, both under the human cytomegolovirus immediate early promoter, as well as the blasticidin resistance gene. Control cells were mock-infected with the empty vector. Infected cells were initially selected in the presence of blasticidin, and then single GFP+ cells were sorted on a flow cytometry device. In this way, we achieved 100% GFP+ subclones that displayed a specific constitutive down-regulation of HSP105, as there was no significant decrease in the expression of its cognate molecular homolog HSP70, or the other major cellular chaperone HSP90. Comparison of the in vitro proliferation rate of two silenced clones with that of the mock culture showed that the cell doubling time of both clones significantly increased and their in vitro growth was accordingly delayed (P= 0.01 and P= 0.04). Western blot analysis in 6 different silenced clones of the oncoproteins most frequently involved in B-NHLs revealed that BCL-6 and c-Myc were down-regulated in function of HSP105 knockdown levels, whereas in mock cells no modifications were detected with respect to their wild-type counterparts. Further strengthening the association between HSP105, BCL-6 and c-Myc expression, immunohistochemistry analysis of 50 primary human aggressive B-NHLs revealed that HSP105 expression, measured both as intensity and percentage of positive cells, was significantly higher in c-Myc- or BCL-6-dependent Burkitt (P= 0.0264) and diffuse large B-cell lymphomas (P= 0.0068) respectively than in other aggressive istotypes that do not overexpress these oncoproteins. These findings support the potential pro-tumorigenic cooperation of HSP105 with BCL-6 and c-Myc transcription factors. To find out whether counteracting HSP105 functions hampers in vivo lymphoma growth, we evaluated the tumor-forming capability of HSP105-silenced (siHSP105) or mock Namalwa cells subcutaneously injected into severe combined immunodeficient mice at serial 10-fold dilutions from 106 to 104 cells/injection (Figure 1). We found that HSP105 knockdown slightly delayed in vivo Namalwa tumor formation when 106 and 105 cells were injected. Noteworthy, no lesions appeared over 70-day observation in mice inoculated with 104 siHSP105 cells, whereas palpable tumors were present in 67% of the animals 24 days after injection of the mock cells (Figure 1). Overall, these results indicate that HSP105 may be a per se nononcogenic molecule that contributes to lymphomagenesis by facilitating the tumorigenic functions of key oncoproteins. They equally provide the rationale for developing HSP105 inhibitors as a novel strategy for improving the treatment of aggressive B-NHLs. Figure 1. In vivo tumor-forming capability of siHSP105 or mock Namalwa cells Figure 1. In vivo tumor-forming capability of siHSP105 or mock Namalwa cells Disclosures: Gianni: Hoffmann-La Roche: Consultancy, Honoraria.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
沦落而发布了新的文献求助10
刚刚
耍酷大山发布了新的文献求助10
刚刚
耍酷大山发布了新的文献求助10
刚刚
耍酷大山发布了新的文献求助10
1秒前
耍酷大山发布了新的文献求助30
1秒前
1秒前
czh给czh的求助进行了留言
2秒前
小柴胡发布了新的文献求助10
2秒前
3秒前
耍酷大山发布了新的文献求助10
3秒前
耍酷大山发布了新的文献求助10
3秒前
4秒前
耍酷大山发布了新的文献求助10
4秒前
耍酷大山发布了新的文献求助10
5秒前
耍酷大山发布了新的文献求助10
6秒前
耍酷大山发布了新的文献求助10
6秒前
耍酷大山发布了新的文献求助10
6秒前
6秒前
耍酷大山发布了新的文献求助10
6秒前
7秒前
耍酷大山发布了新的文献求助10
7秒前
小二郎的应助被土豆采纳,获得10
8秒前
8秒前
科研通AI6.4的应助被养咩咩采纳,获得10
9秒前
科研通AI2S的应助被云隐采纳,获得10
9秒前
9秒前
胖达完成签到,获得积分10
10秒前
耍酷大山发布了新的文献求助10
10秒前
耍酷大山发布了新的文献求助10
10秒前
10秒前
耍酷大山发布了新的文献求助10
10秒前
耍酷大山发布了新的文献求助10
10秒前
耍酷大山发布了新的文献求助10
10秒前
耍酷大山发布了新的文献求助10
11秒前
耍酷大山发布了新的文献求助10
11秒前
耍酷大山发布了新的文献求助10
11秒前
大模型的应助被komorebi采纳,获得10
11秒前
石永怡完成签到,获得积分10
11秒前
科研通AI6.4的应助被呵呵采纳,获得10
11秒前
Hello的应助被唐僧洗发用飘柔采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194415
求助须知:如何正确求助?哪些是违规求助? 9580155
关于积分的说明 21870088
捐赠科研通 7793967
什么是DOI,文献DOI怎么找? 3437647
关于科研通互助平台的介绍 2560986
邀请新用户注册赠送积分活动 2484376